Eloxx Pharmaceuticals Inc expected to post a loss of 17  cents a share - Earnings Preview

Eloxx Pharmaceuticals

07/05/2021 12:40

* Eloxx Pharmaceuticals Inc  ELOX.OQ   ELOX.O  is expected
to show a no change in quarterly revenue when it reports
results .
​* Refinitiv's mean analyst estimate for Eloxx Pharmaceuticals
Inc is for a loss of 17 cents per share. For the same quarter
last year, the company reported a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by
about 11.1% in the last three months. ​
* Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $4.5​, about 54.4% above​ its last
closing price of $2.05. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.16       -0.16      -0.22     Missed  -37.5
 Dec. 31 2020              -0.21      -0.15     Beat    30.2
 Sep. 30 2020  -0.20       -0.19      -0.16     Beat    17.8​
 Jun. 30 2020  -0.21       -0.21      -0.20     Beat    5.5
 Mar.          -0.29​      -0.30      -0.20     Beat    33​
 31​ 2020​                                              
 Dec. 31 2019  -0.32       -0.33      -0.29     Beat    10.9​
 Sep. 30 2019  -0.39       -0.39      -0.32     Beat    18
 Jun. 30 2019  -0.36       -0.36      -0.40     Missed  -11.1
 This summary was machine generated May 7 at 11:40 GMT.  All
figures in US dollars unless otherwise stated